The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
HCV therapy: no one to let behind
Bourlière M1, Pietri O2. Int J Antimicrob Agents. 2018 Dec 31. pii: S0924-8579(18)30380-7. doi: 10.1016/j.ijantimicag.2018.12.010. [Epub ahead of print]
Author information
1
Hepato-gastroenterology department Hospital Saint Joseph, 26 Bd de Louvain 13008 Marseilles France. Electronic address: mbourliere@hopital-saint-joseph.fr.
2
Hepato-gastroenterology department Hospital Saint Joseph, 26 Bd de Louvain 13008 Marseilles France.
Abstract
The advent of oral direct-acting antiviral agents (DAAs) has dramatically improved hepatitis C treatment landscape in the last four years, providing cure rates over 95% with shorter duration of treatment and a very good safety profile. This allowed giving access to treatment in nearly all Hepatitis C virus (HCV) infected patients. The launch of two pangenotypic fixed dose combinations (FDC) in 2017 made a new step forward in hepatitis C treatment by slightly increasing efficacy and more importantly allowing to treat patients without HCV genotyping and in some cases without fibrosis assessment. New triple regimens have solved the issue of retreatment of the few patients who present failure to DAAs therapy. In the present review we describe the current HCV landscape that allows to cure nearly all HCV infected patients.